NASDAQ:RVPH Reviva Pharmaceuticals (RVPH) Stock Price, News & Analysis $1.25 -0.01 (-0.79%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.16▼$1.3050-Day Range$0.98▼$1.5452-Week Range$0.95▼$6.80Volume326,241 shsAverage Volume302,473 shsMarket Capitalization$34.90 millionP/E RatioN/ADividend YieldN/APrice Target$14.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Reviva Pharmaceuticals alerts: Email Address Reviva Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,046.7% Upside$14.33 Price TargetShort InterestBearish12.97% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.98) to ($0.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.08 out of 5 starsMedical Sector626th out of 936 stocksPharmaceutical Preparations Industry288th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingReviva Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageReviva Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Reviva Pharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted12.97% of the outstanding shares of Reviva Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverReviva Pharmaceuticals has a short interest ratio ("days to cover") of 12.8, which indicates bearish sentiment.Change versus previous monthShort interest in Reviva Pharmaceuticals has recently increased by 16.40%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldReviva Pharmaceuticals does not currently pay a dividend.Dividend GrowthReviva Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RVPH. Previous Next 2.7 News and Social Media Coverage News SentimentReviva Pharmaceuticals has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Reviva Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest4 people have searched for RVPH on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Reviva Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders31.83% of the stock of Reviva Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.18% of the stock of Reviva Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Reviva Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Reviva Pharmaceuticals are expected to grow in the coming year, from ($0.98) to ($0.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Reviva Pharmaceuticals is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Reviva Pharmaceuticals is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReviva Pharmaceuticals has a P/B Ratio of 6.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Reviva Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Reviva Pharmaceuticals Stock (NASDAQ:RVPH)Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.Read More RVPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RVPH Stock News HeadlinesJuly 9, 2024 | globenewswire.comReviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary HypertensionMay 30, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 29, 2024 | finance.yahoo.comReviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMay 29, 2024 | globenewswire.comReviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMay 28, 2024 | finance.yahoo.comReviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMay 28, 2024 | globenewswire.comReviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMay 23, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 22, 2024 | finance.yahoo.comRVPH: Enrollment Right Around the CornerMay 21, 2024 | globenewswire.comReviva to Participate in the BIO International ConventionMay 20, 2024 | edition.cnn.comReviva Pharmaceuticals Holdings, Inc.May 16, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHMay 15, 2024 | finance.yahoo.comReviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in SchizophreniaMay 15, 2024 | globenewswire.comReviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in SchizophreniaMay 14, 2024 | investorplace.comRVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q1 2024May 14, 2024 | globenewswire.comReviva Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 13, 2024 | globenewswire.comReviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International ConferenceSee More Headlines Receive RVPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Reviva Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RVPH CUSIPN/A CIK1742927 Webwww.revivapharma.com Phone(408) 501-8881FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price Target$14.33 High Stock Price Target$17.00 Low Stock Price Target$12.00 Potential Upside/Downside+1,046.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,260,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-3,409.55% Return on Assets-294.65% Debt Debt-to-Equity RatioN/A Current Ratio0.93 Quick Ratio0.93 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book6.25Miscellaneous Outstanding Shares27,919,000Free Float19,032,000Market Cap$34.90 million OptionableOptionable Beta-0.09 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Laxminarayan Bhat Ph.D. (Age 59)Founder, CEO, President & Director Comp: $450kMr. Narayan Prabhu (Age 52)Chief Financial Officer Comp: $325kKey CompetitorsI-MabNASDAQ:IMABKaryopharm TherapeuticsNASDAQ:KPTICellectisNASDAQ:CLLSCytomX TherapeuticsNASDAQ:CTMXOramed PharmaceuticalsNASDAQ:ORMPView All CompetitorsInstitutional OwnershipTorno Capital LLCSold 10,000 shares on 5/15/2024Ownership: 0.000%Vanguard Group Inc.Bought 26,854 shares on 5/10/2024Ownership: 3.588%View All Institutional Transactions RVPH Stock Analysis - Frequently Asked Questions How have RVPH shares performed this year? Reviva Pharmaceuticals' stock was trading at $5.15 at the start of the year. Since then, RVPH shares have decreased by 75.7% and is now trading at $1.25. View the best growth stocks for 2024 here. How were Reviva Pharmaceuticals' earnings last quarter? Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) announced its earnings results on Tuesday, May, 14th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.03. How do I buy shares of Reviva Pharmaceuticals? Shares of RVPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RVPH) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reviva Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Reviva Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RVPH Stock Alerts